MCID: RST020
MIFTS: 21

Restless Legs Syndrome 6

Categories: Rare diseases

Aliases & Classifications for Restless Legs Syndrome 6

MalaCards integrated aliases for Restless Legs Syndrome 6:

Name: Restless Legs Syndrome 6 54 71
Restless Legs Syndrome, Susceptibility to, 6 50 13
Rls6 50 71
Periodic Limb Movements in Sleep 50

Classifications:



External Ids:

OMIM 54 611185
MedGen 40 C1970020
MeSH 42 D012148

Summaries for Restless Legs Syndrome 6

OMIM : 54
Restless legs syndrome (RLS) is a neurologic disorder characterized by an uncontrollable urge to move the legs during periods of rest. The majority of patients with RLS also have periodic limb movements in sleep, which are characterized by involuntary, highly stereotypical, regularly occurring limb movements that occur during sleep. Limb movements during sleep are more common in otherwise asymptomatic family members of patients with RLS compared to the general population (Stefansson et al., 2007). Thus, periodic limb movements during sleep may serve as an endophenotype for RLS. However, not all patients with RLS have limb movements during sleep, and the majority of individuals with limb movements during sleep do not have waking symptoms of RLS (Winkelman, 2007). For additional information and a discussion of genetic heterogeneity of RLS, see RLS1 (102300). (611185)

MalaCards based summary : Restless Legs Syndrome 6, also known as restless legs syndrome, susceptibility to, 6, is related to restless legs syndrome 7 and restless legs syndrome. An important gene associated with Restless Legs Syndrome 6 is RLS6 (Restless Legs Syndrome, Susceptibility To, 6). The drugs Dopamine and Pramipexole have been mentioned in the context of this disorder. Affiliated tissues include bone and skin.

UniProtKB/Swiss-Prot : 71 Restless legs syndrome 6: A neurologic sleep/wake disorder characterized by uncomfortable and unpleasant sensations in the legs that appear at rest, usually at night, inducing an irresistible desire to move the legs. The disorder results in nocturnal insomnia and chronic sleep deprivation. The majority of patients also have periodic limb movements in sleep, which are characterized by involuntary, highly stereotypical, regularly occurring limb movements that occur during sleep.

Related Diseases for Restless Legs Syndrome 6

Diseases related to Restless Legs Syndrome 6 via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 restless legs syndrome 7 10.9
2 restless legs syndrome 10.2
3 periodic limb movement disorder 10.0
4 attention deficit-hyperactivity disorder 9.8
5 neuroma 9.8
6 cleidocranial dysplasia 9.5 BTBD9 RLS6

Graphical network of the top 20 diseases related to Restless Legs Syndrome 6:



Diseases related to Restless Legs Syndrome 6

Symptoms & Phenotypes for Restless Legs Syndrome 6

Clinical features from OMIM:

611185

Drugs & Therapeutics for Restless Legs Syndrome 6

Drugs for Restless Legs Syndrome 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 89)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1 51-61-6, 62-31-7 681
2
Pramipexole Approved, Investigational Phase 4,Phase 3,Phase 2 104632-26-0 59868 119570
3
Ropinirole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 91374-20-8, 91374-21-9 5095 497540
4
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 1 60142-96-3 3446
5
gamma-Aminobutyric acid Investigational Phase 4,Phase 1 56-12-2 119
6 Antioxidants Phase 4,Phase 3,Phase 2
7 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Dopamine agonists Phase 4,Phase 3,Phase 2,Phase 1
10 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
11 Protective Agents Phase 4,Phase 3,Phase 2
12 N 0437 Phase 4,Phase 3,Phase 2
13 Autonomic Agents Phase 4
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
15 Analgesics Phase 4,Phase 2,Phase 1
16 Anti-Anxiety Agents Phase 4,Phase 2,Phase 1
17 Anticonvulsants Phase 4,Phase 2,Phase 1
18 Antimanic Agents Phase 4,Phase 1
19 calcium channel blockers Phase 4,Phase 2,Phase 1
20 Calcium, Dietary Phase 4,Phase 2,Phase 1
21 Central Nervous System Depressants Phase 4,Phase 2,Phase 1
22 Excitatory Amino Acid Antagonists Phase 4,Phase 1
23 Excitatory Amino Acids Phase 4,Phase 1
24 GABA Agents Phase 4,Phase 1
25 Psychotropic Drugs Phase 4,Phase 2,Phase 3,Phase 1
26 Tranquilizing Agents Phase 4,Phase 2,Phase 1
27 Analgesics, Opioid Phase 4,Phase 1
28 Narcotics Phase 4,Phase 1
29
Lisuride Approved Phase 3 18016-80-3 28864
30
Cabergoline Approved Phase 3 81409-90-7 54746
31
Levodopa Approved Phase 3 59-92-7 6047
32
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
33
Bupropion Approved Phase 2, Phase 3 34841-39-9, 34911-55-2 444
34 tannic acid Approved, Nutraceutical Phase 3
35
Cholecalciferol Approved, Nutraceutical Phase 2, Phase 3 67-97-0 6221 10883523 5280795
36
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
37
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
38
Serotonin Phase 3 50-67-9 5202
39 Serotonin Agents Phase 3
40 Antidepressive Agents Phase 2, Phase 3
41 Antidepressive Agents, Second-Generation Phase 2, Phase 3
42 Cytochrome P-450 CYP2D6 Inhibitors Phase 2, Phase 3
43 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
44 Dopamine Uptake Inhibitors Phase 2, Phase 3
45 Neurotransmitter Uptake Inhibitors Phase 2, Phase 3
46 Micronutrients Phase 2, Phase 3
47 Trace Elements Phase 2, Phase 3
48 Bone Density Conservation Agents Phase 2, Phase 3
49 Ergocalciferols Phase 2, Phase 3
50 Vitamins Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 52)

id Name Status NCT ID Phase Drugs
1 A 6 Week Trial to Study the Efficacy and Safety of a Starting Dose 0.25 mg Pramipexole (Mirapex) in Patients With RLS Completed NCT00375284 Phase 4 Pramipexole
2 Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT00472199 Phase 4 Pramipexole;Placebo
3 Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
4 A Phase IV Trial With Pramipexole to Investigate the Effects on RLS Symptoms and Sleep Disturbance in Patients With RLS Completed NCT00349531 Phase 4 Pramipexole
5 Phase IV Trial With Pramipexole to Evaluate Safety and Efficacy in Patients With RLS Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
6 Switching From Oral Dopamine Agonists to Rotigotine Completed NCT01976871 Phase 4 Rotigotine
7 An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS Recruiting NCT02560766 Phase 4 HORIZANT 300 mg;HORIZANT 600 mg;Placebo
8 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
9 A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.) Completed NCT00152958 Phase 3 Pramipexole
10 Pramipexole in Out-patients With Idiopathic Restless Legs Syndrome (IRLS) Completed NCT00654498 Phase 3 Pramipexole;Placebo
11 Efficacy and Safety of Pramipexole (PPX) in Moderate to Severe Idiopathic Restless Legs Syndrome (RLS) Patients Completed NCT00275457 Phase 3 pramipexole
12 A Randomised, Comparing Fixed Doses of Pramipexole to Investigate the Efficacy and Safety in Patients With RLS. Completed NCT00390689 Phase 3 Pramipexole 0.125 mg tablet;Pramipexole 0.5 mg tablet
13 Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS) Completed NCT01569464 Phase 3 Rotigotine
14 Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects Completed NCT00498108 Phase 3 Rotigotine
15 Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome Completed NCT00136045 Phase 3 Rotigotine
16 Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome Completed NCT00355641 Phase 3 Ropinirole Extended Release (XR)
17 Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
18 Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00367822 Phase 3 Lisuride;Ropinirole;Placebo
19 A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS Completed NCT00625547 Phase 3 cabergoline;levodopa
20 A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis Completed NCT01537042 Phase 3 Rotigotine;Placebo
21 The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome Completed NCT00357097 Phase 3 Ropinirole
22 A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS Completed NCT00627003 Phase 3 Cabergoline
23 Bupropion and Restless Legs Syndrome Completed NCT00621517 Phase 2, Phase 3 Bupropion;Placebo
24 Vitamin D in the Treatment of Primary Restless Legs Syndrome Not yet recruiting NCT02256215 Phase 2, Phase 3 Vitamin D
25 Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome Completed NCT00152997 Phase 2 Pramipexole 0.125 mg tablets;Pramipexole 0.125 mg tablets Placebo
26 Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients Completed NCT00676403 Phase 2 placebo;Pregabalin;Pregabalin;Pregabalin;Pregabalin;Pregabalin
27 The Effects of Aplindore on the Treatment of Signs and Symptoms of Restless Legs Syndrome Completed NCT00626418 Phase 2 Aplindore;Placebo
28 Study of Istradefylline (KW-6002) for the Treatment of Restless Legs Syndrome Completed NCT00199446 Phase 2 Istradefylline (KW-6002)
29 A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients Completed NCT00666965 Phase 2 SPM 962
30 Rotigotine Restless Legs Syndrome Dose Finding Trial Completed NCT00243217 Phase 2 SPM 936
31 Botulinum Toxin to Treat Restless Legs Syndrome Completed NCT00479154 Phase 1, Phase 2 Botulinum Toxin A
32 A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome Completed NCT01562743 Phase 2 SPM 962
33 Clinical Evaluation of Ropinirole CR-RLS ( SK&F101468)Tablets in Restless Legs Syndrome Completed NCT00530790 Phase 2 ropinirole controlled release (CR)-RLS
34 Restless Legs Syndrome Treatment With Botulinum Toxin Completed NCT00949806 Phase 2 BNT (intradermal injection)
35 Iron Sucrose In The Treatment of Restless Legs Syndrome: Safety of Three Dose Regimens as Evaluated by Clinical Assessments Completed NCT00895232 Phase 2 Cohort I;Cohort II;Cohort III
36 Dose-Response and Pharmacokinetics of Gabapentin Enacarbil (GEn [XP13512 / GSK1838262]) in Restless Legs Syndrome Completed NCT01332305 Phase 2 GEn (XP13512/GSK1838262);Placebo
37 Precutaneous High Risk Patent Foramen Ovale to Treat Migraine Headaches Recruiting NCT02777359 Phase 2
38 Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist Not yet recruiting NCT03218969 Phase 1, Phase 2 Ecopipam;Placebo
39 Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome Terminated NCT00834327 Phase 2 aplindore MR tablets or Placebo
40 IV Iron Treatment of Restless Legs Syndrome Withdrawn NCT02484768 Phase 2 Iron isomaltoside 1000;Sodium Chloride 0.9%
41 Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food Completed NCT00419692 Phase 1 Ropinirole
42 Drug Drug Interaction Study With Gabapentin Enacarbil and Morphine Completed NCT01476124 Phase 1 morphine Placebo;GEn 600 mg;Morphine;GEn Placebo
43 RISCA : Prospective Study of Individuals at Risk for SCA1, SCA2, SCA3, SCA6, SCA7 Unknown status NCT01037777
44 Implementation of an Integrated Primary Care Network for Prevention and Management of Cardiometabolic Risks Unknown status NCT01326130
45 Non-interventional Observational Study on the Influence of Pramipexole on Sensory Symptoms of Restless Legs Syndrome (RLS) Completed NCT00887289
46 Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS) Completed NCT02248142 Pramipexole
47 Relationship Between Sensory and Motor Systems in Restless Leg Syndrome Completed NCT00074672
48 Effect on RLS Symptom Severity After Switching to Neupro® in Patients Who Previously Experienced Augmentation Completed NCT01386944
49 Prevalence of OSAS in Chinese Elderly and Its CPAP Compliance Completed NCT02085720
50 Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome Completed NCT01174459

Search NIH Clinical Center for Restless Legs Syndrome 6

Genetic Tests for Restless Legs Syndrome 6

Anatomical Context for Restless Legs Syndrome 6

MalaCards organs/tissues related to Restless Legs Syndrome 6:

39
Bone, Skin

Publications for Restless Legs Syndrome 6

Variations for Restless Legs Syndrome 6

Expression for Restless Legs Syndrome 6

Search GEO for disease gene expression data for Restless Legs Syndrome 6.

Pathways for Restless Legs Syndrome 6

GO Terms for Restless Legs Syndrome 6

Sources for Restless Legs Syndrome 6

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....